top of page


Director Preclinical Development

Matthew D. Reed, PhD, DABT, Fellow-ATS is a pharmacologist, board certified toxicologist, and Fellow of the Academy of Toxicology Sciences.  He has over 23+ years of experience investigating nonclinical and translational inhaled aerosol delivery.   


Dr Reed currently holds/has held senior roles as a respiratory drug development consultant at Coelus, CSO of Nob Hill Therapeutics, and VP of Development at Kinnear Therapeutics. He was formerly Vice President, Applied Toxicology and Nonclinical Development and Director, Preclinical Drug Development at Lovelace Biomedical, where he focused on applied toxicology questions, early-phase pharmaceutical transitions, pharmaceutical IP development, and pharmaceutical research and development services.  In these roles Dr Reed has overseen and consulted on all aspects of nonclinical-early translational inhaled drug delivery including formulation/device feasibility and development, pharmacokinetics, pharmacology, safety pharmacology, animal models of pulmonary, cardiovascular, and infectious diseases, etc., and pivotal IND and NDA GLP compliant studies.  He has developed inhaled oligonucleotides, siRNA, gene therapy, proteins, peptides, and multiple small molecules over his career.


Dr Reed is the author of over 120 scientific publications and abstracts and has been awarded/managed over $60M USD in drug development-focused government/foundation grants. 


Matthew will facilitate RAGE’s efforts in nonclinical development.

Matt Reed LinkedIn pic_edited.png
Matt Reed: TeamMember
bottom of page